Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Auranofin Suppresses Plasminogen Activator Inhibitor-2 Expression through Annexin A5 Induction in Human Prostate Cancer Cells

  • Received : 2016.09.30
  • Accepted : 2016.10.17
  • Published : 2017.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Auranofin has been developed as antirheumatic drugs, which is currently under clinical development for the treatment of chronic lymphocytic leukemia. Previous report showed that auranofin induced apoptosis by enhancement of annexin A5 expression in PC-3 cells. To understand the role of annexin A5 in auranofin-mediated apoptosis, we performed microarray data analysis to study annexin A5-controlled gene expression in annexin A5 knockdown PC-3 cells. Of differentially expressed genes, plasminogen activator inhibitor (PAI)-2 was increased by annexin A5 siRNA confirmed by qRT-PCR and western blot. Treatment with auranofin decreased PAI-2 and increased annexin A5 expression as well as promoting apoptosis. Furthermore, auranofin-induced apoptosis was recovered by annexin A5 siRNA but it was promoted by PAI-2 siRNA. Interestingly, knockdown of annexin A5 rescued PAI-2 expression suppressed by auranofin. Taken together, our study suggests that induction of annexin A5 by auranofin may enhance apoptosis through suppression of PAI-2 expression in PC-3 cells.

Keywords

References

  1. Boersma, H. H., Kietselaer, B. L., Stolk, L. M., Bennaghmouch, A., Hofstra, L., Narula, J., Heidendal, G. A. and Reutelingsperger, C. P. (2005) Past, present, and future of annexin A5: from protein discovery to clinical applications. J. Nucl. Med. 46, 2035-2050.
  2. Bohn, H. and Kraus, W. (1979) Isolation and characterization of a new placenta specific protein (PP10) (author's transl). Arch. Gynecol. 227, 125-134. https://doi.org/10.1007/BF02103286
  3. Bolstad, B. M., Irizarry, R. A., Astrand, M. and Speed, T. P. (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185-193. https://doi.org/10.1093/bioinformatics/19.2.185
  4. Cardo-Vila, M., Arap, W. and Pasqualini, R. (2003) ${\alpha}v{\beta}5$ integrin-dependent programmed cell death triggered by a peptide mimic of annexin V. Mol. Cell 11, 1151-1162. https://doi.org/10.1016/S1097-2765(03)00138-2
  5. Clinicaltrials.gov (2016) Phase I and II study of auranofin in chronic lymphocytic leukemia (CLL). Available from: https://clinicaltrials.gov/ct2/show/NCT01419691/.
  6. Croucher, D. R., Saunders, D. N., Lobov, S. and Ranson, M. (2008) Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat. Rev. Cancer 8, 535-545. https://doi.org/10.1038/nrc2400
  7. Demange, P., Voges, D., Benz, J., Liemann, S., Göttig, P., Berendes, R., Burger, A. and Huber, R. (1994) Annexin V: the key to understanding ion selectivity and voltage regulation? Trends Biochem. Sci. 19, 272-276. https://doi.org/10.1016/0968-0004(94)90002-7
  8. Dickinson, J. L., Bates, E. J., Ferrante, A. and Antalis, T. M. (1995) Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor ${\alpha}$-induced apoptosis. J. Biol. Chem. 270, 27894-27904. https://doi.org/10.1074/jbc.270.46.27894
  9. Eisen, M. B., Spellman, P. T., Brown, P. O. and Botstein, D. (1998) Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U.S.A. 95, 14863-14868. https://doi.org/10.1073/pnas.95.25.14863
  10. Ganesh, S., Sier, C. F., Griffioen, G., Vloedgraven, H. J., de Boer, A., Welvaart, K., van de Velde, C. J., van Krieken, J. H., Verheijen, J. H., Lamers, C. B. H. W. and Verspaget, H. W. (1994) Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res. 54, 4065-4071.
  11. Han, S., Kim, K., Kim, H., Kwon, J., Lee, Y. H., Lee, C. K., Song, Y., Lee, S. J., Ha, N. and Kim, K. (2008) Auranofin inhibits overproduction of pro-inflammatory cytokines, cyclooxygenase expression and PGE2 production in macrophages. Arch. Pharm. Res. 31, 67-74. https://doi.org/10.1007/s12272-008-1122-9
  12. Hong, M., Park, N. and Chun, Y. J. (2014) Role of annexin a5 on mitochondria-dependent apoptosis induced by tetramethoxystilbene in human breast cancer cells. Biomol. Ther. (Seoul) 22, 519-524. https://doi.org/10.4062/biomolther.2014.112
  13. Irizarry, R. A., Hobbs, B., Collin, F., Beazer-Barclay, Y. D., Antonellis, K. J., Scherf, U. and Speed, T. P. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264. https://doi.org/10.1093/biostatistics/4.2.249
  14. Irving, J. A., Pike, R. N., Lesk, A. M. and Whisstock, J. C. (2000) Phylogeny of the serpin superfamily: implications of patterns of amino acid conservation for structure and function. Genome Res. 10, 1845-1864. https://doi.org/10.1101/gr.GR-1478R
  15. Jeon, K. I., Jeong, J. Y. and Jue, D. M. (2000) Thiol-reactive metal compounds inhibit NF-${\kappa}B$ activation by blocking $I{\kappa}B$ kinase. J. Immunol. 164, 5981-5989. https://doi.org/10.4049/jimmunol.164.11.5981
  16. Jeong, J. J., Park, N., Kwon, Y. J., Ye, D. J., Moon, A. and Chun, Y. J. (2014) Role of annexin A5 in cisplatin-induced toxicity in renal cells: molecular mechanism of apoptosis. J. Biol. Chem. 289, 2469-2481. https://doi.org/10.1074/jbc.M113.450163
  17. Jing, J., Chen, L., Fu, H. Y., Fan, K., Yao, Q., Ge Y. F., Lu, J. C. and Yao, B. (2015) Annexin V-induced rat Leydig cell proliferation involves Ect2 via RhoA/ROCK signaling pathway. Sci. Rep. 5, 9437. https://doi.org/10.1038/srep09437
  18. Kean, W. F., Hart, L. and Buchanan, W. W. (1997) Auranofin. Br. J. Rheumatol. 36, 560-572. https://doi.org/10.1093/rheumatology/36.5.560
  19. Kim, N. H., Lee, M. Y., Park, S. J., Choi, J. S., Oh, M. K. and Kim, I. S. (2007) Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3. Immunology 122, 607-614. https://doi.org/10.1111/j.1365-2567.2007.02679.x
  20. Koopman, G., Reutelingsperger, C. P., Kuijten, G. A., Keehnen, R. M., Pals, S. T. and van Oers, M. H. (1994) Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84, 1415-1420.
  21. Kruithof, E. K., Baker, M. S. and Bunn, C. L. (1995) Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 86, 4007-4024.
  22. Kumar, S. and Baglioni, C. (1991) Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. J. Biol. Chem. 266, 20960-20964.
  23. Kwon, Y. J., Jung, J. J., Park, N. H., Ye, D. J., Kim, D., Moon, A. and Chun, Y. J. (2013) Annexin A5 as a new potential biomarker for cisplatin-induced toxicity in human kidney epithelial cells. Biomol. Ther. (Seoul) 21, 190-195. https://doi.org/10.4062/biomolther.2013.026
  24. Li, H., Hu, J., Wu, S., Wang, L., Cao, X., Zhang, X., Dai, B., Cao, M., Shao, R., Zhang, R., Majidi, M., Ji, L., Heymach, J. V., Wang, M., Pan, S., Minna, J., Mehran, R. J., Swisher, S. G., Roth, J. A. and Fang, B. (2016) Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget 7, 3548-3558. https://doi.org/10.18632/oncotarget.6516
  25. Liu, N., Li, X., Huang, H., Zhao, C., Liao, S., Yang, C., Liu, S., Song, W., Lu, X., Lan, X., Chen, X., Yi, S., Xu, L., Jiang, L., Zhao, C., Dong, X., Zhou, P., Li, S., Wang, S., Shi, X., Dou, P. Q., Wang, X. and Liu, J. (2014) Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget 5, 5453-5471. https://doi.org/10.18632/oncotarget.2113
  26. Mahoney, C. W., Hensey, C. E. and Azzi, A. (1989) Auranofin, gold thiomalate, and gold thioglucose inhibit protein kinase C. Biochem. Pharmacol. 38, 3383-3386. https://doi.org/10.1016/0006-2952(89)90638-2
  27. Marzano, C., Gandin, V., Folda, A., Scutari, G., Bindoli, A. and Rigobello, M. P. (2007) Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic. Biol. Med. 42, 872-881. https://doi.org/10.1016/j.freeradbiomed.2006.12.021
  28. Medcalf, R. L. and Stasinopoulos, S. J. (2005) The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2. FEBS J. 272, 4858-4867. https://doi.org/10.1111/j.1742-4658.2005.04879.x
  29. Nakaya, A., Sagawa, M., Muto, A., Uchida, H., Ikeda, Y. and Kizaki, M. (2011) The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-${\kappa}B$ activity. Leuk. Res. 35, 243-249. https://doi.org/10.1016/j.leukres.2010.05.011
  30. Nordengren, J., Fredstorp Lidebring, M., Bendahl, P. O., Brunner, N., Fernö, M., Hogberg, T., Stephens, R. W., Wilen, R. and Casslen, B. (2002) High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer. Int. J. Cancer 97, 379-385. https://doi.org/10.1002/ijc.1611
  31. Park, N. and Chun, Y. J. (2014) Auranofin promotes mitochondrial apoptosis by inducing annexin A5 expression and translocation in human prostate cancer cells. J. Toxicol. Environ. Health Part A 77, 1467-1476. https://doi.org/10.1080/15287394.2014.955834
  32. Park, S. H., Lee, J. H., Berek, J. S. and Hu, M. C. (2014) Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53. Int. J. Oncol. 45, 1691-1698. https://doi.org/10.3892/ijo.2014.2579
  33. Reutelingsperger, C. P., Hornstra, G. and Hemker, H. C. (1985) Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. Eur. J. Biochem. 151, 625-629. https://doi.org/10.1111/j.1432-1033.1985.tb09150.x
  34. Rothhut, B., Dubois, T., Feliers, D., Russo-Marie, F. and Oudinet, J. P. (1995) Inhibitory effect of annexin V on protein kinase C activity in mesangial cell lysates. Eur. J. Biochem. 232, 865-872. https://doi.org/10.1111/j.1432-1033.1995.tb20885.x
  35. Silverman, G. A., Jockel, J. I., Domer, P. H., Mohr, R. M., Taillon-Miller, P. and Korsmeyer, S. J. (1991) Yeast artificial chromosome cloning of a two-megabase-size contig within chromosomal band 18q21 establishes physical linkage between BCL2 and plasminogen activator inhibitor type-2. Genomics 9, 219-228. https://doi.org/10.1016/0888-7543(91)90245-A
  36. Stern, I., Wataha, J. C., Lewis, J. B., Messer, R. L. W., Lockwood, P. E. and Tseng, W. Y. (2005) Anti-rheumatic gold compounds as sublethal modulators of monocytic LPS-induced cytokine secretion. Toxicol. In Vitro 19, 365-371. https://doi.org/10.1016/j.tiv.2004.11.001
  37. Stringer, B., Udofa, E. A. and Antalis, T. M. (2012) Regulation of the human plasminogen activator inhibitor type 2 gene: cooperation of an upstream silencer and transactivator. J. Biol. Chem. 287, 10579-10589. https://doi.org/10.1074/jbc.M111.318758
  38. Vermes, I., Haanen, C., Steffens-Nakken, H. and Reutelingsperger, C. (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 184, 39-51. https://doi.org/10.1016/0022-1759(95)00072-I
  39. Zhou, H. M., Bolon, I., Nichols, A., Wohlwend, A. and Vassalli, J. D. (2001) Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice. Cancer Res. 61, 970-976.

Cited by

  1. The Neuroprotective Role of MiR-124-3p in a 6-Hydroxydopamine-Induced Cell Model of Parkinson's Disease via the Regulation of ANAX5 vol.119, pp.1, 2018, https://doi.org/10.1002/jcb.26170
  2. Overexpression of GRK3, Promoting Tumor Proliferation, Is Predictive of Poor Prognosis in Colon Cancer vol.2017, pp.1875-8630, 2017, https://doi.org/10.1155/2017/1202710
  3. Expression of annexin A5 in serum and tumor tissue of patients with colon cancer and its clinical significance vol.23, pp.39, 2017, https://doi.org/10.3748/wjg.v23.i39.7168
  4. Thioredoxin Confers Intrinsic Resistance to Cytostatic Drugs in Human Glioma Cells vol.19, pp.10, 2018, https://doi.org/10.3390/ijms19102874
  5. AnnexinA5 promote glioma cell invasion and migration via the PI3K/Akt/NF-κB signaling pathway vol.138, pp.3, 2018, https://doi.org/10.1007/s11060-018-2818-4
  6. Impact of ANXA5 polymorphisms on glioma risk and patient prognosis vol.142, pp.1, 2017, https://doi.org/10.1007/s11060-018-03069-9
  7. Gomisin G Suppresses the Growth of Colon Cancer Cells by Attenuation of AKT Phosphorylation and Arrest of Cell Cycle Progression vol.27, pp.2, 2017, https://doi.org/10.4062/biomolther.2018.054
  8. Combination treatment with auranofin and nutlin-3a induces synergistic cytotoxicity in breast cancer cells vol.82, pp.10, 2017, https://doi.org/10.1080/15287394.2019.1635934
  9. Calcium relieves fluoride-induced bone damage through the PI3K/AKT pathway vol.11, pp.1, 2017, https://doi.org/10.1039/c9fo02491c
  10. Loss of Annexin A5 expression attenuates the lipopolysaccharide‐induced inflammatory response of rat alveolar macrophages vol.44, pp.2, 2020, https://doi.org/10.1002/cbin.11239
  11. Glucocorticoid resistance induced by ANXA5 overexpression in B-cell acute lymphoblastic leukemia vol.38, pp.1, 2021, https://doi.org/10.1080/08880018.2020.1810182